- Home
- CNFR vs SNSE Comparison
CNFR vs SNSE Comparison
Compare CNFR & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNFR
- SNSE
- Stock Information
- Founded
- CNFR 2009
- SNSE 2005
- Country
- CNFR United States
- SNSE United States
- Employees
- CNFR N/A
- SNSE N/A
- Industry
- CNFR Property-Casualty Insurers
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- CNFR Finance
- SNSE Health Care
- Exchange
- CNFR Nasdaq
- SNSE Nasdaq
- Market Cap
- CNFR 11.4M
- SNSE 12.5M
- IPO Year
- CNFR 2015
- SNSE 2021
- Fundamental
- Price
- CNFR $0.43
- SNSE $0.33
- Analyst Decision
- CNFR
- SNSE Strong Buy
- Analyst Count
- CNFR 0
- SNSE 4
- Target Price
- CNFR N/A
- SNSE $4.25
- AVG Volume (30 Days)
- CNFR 21.5K
- SNSE 8.1M
- Earning Date
- CNFR 05-13-2025
- SNSE 03-28-2025
- Dividend Yield
- CNFR N/A
- SNSE N/A
- EPS Growth
- CNFR N/A
- SNSE N/A
- EPS
- CNFR 1.92
- SNSE N/A
- Revenue
- CNFR $66,771,000.00
- SNSE N/A
- Revenue This Year
- CNFR $24.98
- SNSE N/A
- Revenue Next Year
- CNFR N/A
- SNSE N/A
- P/E Ratio
- CNFR $0.25
- SNSE N/A
- Revenue Growth
- CNFR N/A
- SNSE N/A
- 52 Week Low
- CNFR $0.45
- SNSE $0.25
- 52 Week High
- CNFR $1.91
- SNSE $1.94
- Technical
- Relative Strength Index (RSI)
- CNFR 27.57
- SNSE 34.32
- Support Level
- CNFR $0.45
- SNSE $0.30
- Resistance Level
- CNFR $0.68
- SNSE $0.76
- Average True Range (ATR)
- CNFR 0.09
- SNSE 0.07
- MACD
- CNFR -0.01
- SNSE -0.01
- Stochastic Oscillator
- CNFR 21.32
- SNSE 14.14
About CNFR Conifer Holdings Inc.
Conifer Holdings Inc is an insurance company engaged in the sale of property and casualty insurance products. It is engaged in three classes of insurance businesses namely commercial lines, personal lines, and wholesale agency business. Within these three businesses, the company offers various insurance products and insurance agency services. The company views the commercial and personal lines segments as underwriting business. The wholesale agency business provides non-risk bearing revenue through commissions and policy fees. Its revenues are derived from premiums earned from insurance operations.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.